



**PERENNIAL TREASURY PTE. LTD.**  
(Incorporated in the Republic of Singapore)  
(Company Registration No. 201326018H)

---

**S\$25,000,000 5.75% NOTES DUE 2028 ISSUED PURSUANT TO THE S\$2,000,000,000  
MULTICURRENCY DEBT ISSUANCE PROGRAMME OF PERENNIAL TREASURY PTE. LTD. AND  
PERENNIAL HOLDINGS PRIVATE LIMITED (TO BE CONSOLIDATED AND FORM A SINGLE  
SERIES WITH THE EXISTING S\$125,000,000 5.75% NOTES DUE 2028 ISSUED ON 7 APRIL 2025  
AND THE S\$50,000,000 5.75% NOTES DUE 2028 ISSUED ON 21 MAY 2025)**

---

Further to the announcement by Perennial Treasury Pte. Ltd. (the "**Issuer**") on 25 June 2025, the Board of Directors of the Issuer wishes to announce that it has issued S\$25,000,000 in aggregate principal amount of 5.75% notes due 2028 (the "**Series 12 Tranche 003 Notes**") (to be consolidated and form a single series with the existing S\$125,000,000 5.75% notes due 2028 issued on 7 April 2025 (the "**Series 12 Tranche 001 Notes**") and the S\$50,000,000 5.75% notes due 2028 issued on 21 May 2025 (the "**Series 12 Tranche 002 Notes**")). The Series 12 Tranche 003 Notes were issued by the Issuer, as issuer, and guaranteed by Perennial Holdings Private Limited, as guarantor, pursuant to the S\$2,000,000,000 Multicurrency Debt Issuance Programme established by the Issuer and Perennial Holdings Private Limited on 22 January 2015 and updated on 27 March 2025 (the "**Programme**"). DBS Bank Ltd. was appointed as the sole lead manager and bookrunner in relation to the Series 12 Tranche 003 Notes.

Approval in-principle has been received from the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") for the listing and quotation of the Series 12 Tranche 003 Notes on the SGX-ST. The SGX-ST assumes no responsibility for the correctness of any of the statements made, opinions expressed or reports contained herein. Approval in-principle from, admission to the Official List of, and the listing and quotation of the Series 12 Tranche 003 Notes on, the SGX-ST are not to be taken as an indication of the merits of the Issuer, Perennial Holdings Private Limited, their respective subsidiaries, associated companies (if any), and joint venture companies (if any), the Programme or the Series 12 Tranche 003 Notes. The Series 12 Tranche 003 Notes are expected to be listed on 2 July 2025.

For and on behalf of  
The Board of Directors

**PERENNIAL TREASURY PTE. LTD.**  
1 July 2025

### **About Perennial Treasury Pte. Ltd.**

Perennial Treasury Pte. Ltd. is a wholly-owned subsidiary of Perennial Holdings Private Limited ("**Perennial Holdings**"). Perennial Holdings is an established integrated healthcare and real estate company headquartered in Singapore. Perennial Holdings owns, manages and operates over 25,000 beds in medical and eldercare facilities, comprising about 16,000 operational beds and over 9,000 beds in the pipeline, across 15 cities in China and Singapore. In China, Perennial Holdings owns and operates the country's first private integrated healthcare ecosystem, which combines a unique medical platform centred on partnerships with doctors and one of the largest private integrated eldercare platforms in the country. Its comprehensive medical care facilities encompass general, rehabilitation, specialist and nursing hospitals, while its eldercare facilities include independent living, assisted living, nursing homes and dementia care. In Singapore, Perennial Holdings will operate the nation's first private assisted living development and is set to launch the country's first-of-its-kind private integrated rehabilitation and traditional Chinese medicine wellness facility.

Perennial Holdings' quality real estate portfolio spans over 84 million square feet in total gross floor area across China, Singapore, Malaysia and Indonesia. Perennial Holdings focuses strategically on large-scale transit-oriented developments ("**TODs**"), serving as enablers of its healthcare portfolio, and landmark integrated developments. It has six TODs in China which are connected to high-speed railway ("**HSR**") stations, of which five located in Tianjin, Chengdu, Kunming, Xi'an and Chongqing, are healthcare-centric, and one commercial-centric HSR TOD is in Hangzhou.